ReviewInvestigative and clinical urology2016
Treatment of bladder cancer in the elderly.
Review in Investigative and clinical urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Role of adjuvant cisplatin-based chemotherapy following radical cystectomy in locally advanced muscle-invasive bladder cancer: Systematic review and meta-analysis of randomized trials.Investigative and clinical urology · 2019Pooled it
- Impact of small area-level deprivation on survival outcomes in patients with Cholangiocarcinoma: a population-based multilevel survival analysis.Frontiers in public health · 2026Article
- The effect of different adipose tissue measurements on clinical prognosis in bladder cancer patients undergoing radical cystectomy: preliminary results.Abdominal radiology (New York) · 2025Article
- Clinical and Pathological Characteristics of Bladder Cancer in Patients Aged 18-45 Undergoing Transurethral Resection of Bladder Tumor.Biomedicines · 2024Article
- Elderly and bladder cancer: The role of radical cystectomy and orthotopic urinary diversion.Urologia · 2024Review
- Low adherence to recommended use of neoadjuvant chemotherapy for muscle-invasive bladder cancer.World journal of urology · 2023Article
- Non-metastatic muscle-invasive bladder cancer: the role of age in receiving treatment with curative intent.BJU international · 2022Article
- Exploiting dietary fibre and the gut microbiota in pelvic radiotherapy patients.British journal of cancer · 2022Review
- Clinical outcome and quality of life in octogenarian patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy or transurethral resection of the bladder tumor: a retrospective analysis of 143 patients.International urology and nephrology · 2022Article
- Comparative Analysis of Elderly Patients Undergoing Radical Cystectomy With Ureterocutaneostomy or Ileal Conduit With a Special Focus on Bowl Complications Requiring Surgical Revision.Frontiers in surgery · 2022Article
- Decreasing Non-bladder-cancer Mortality After Radical Cystectomy.European urology open science · 2021Article
- ASR488, a novel small molecule, activates an mRNA binding protein, CPEB1, and inhibits the growth of bladder cancer.Oncology letters · 2020Article
- Non-Muscle Invasive Bladder Cancer: A Review of the Current Trend in Africa.World journal of oncology · 2019Review
- Long non-coding RNA CDKN2B antisense RNA 1 gene inhibits Gemcitabine sensitivity in bladder urothelial carcinoma.Journal of Cancer · 2018Article
- Review
- LncRNA plasmacytoma variant translocation 1 is an oncogene in bladder urothelial carcinoma.Oncotarget · 2017Article
- Changing landscape of diagnosis and treatment of bladder cancer.Investigative and clinical urology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As the population ages and life expectancy increases in the human population, more individuals will be diagnosed with bladder cancer (BC). The definition of who is elderly is likely to change in the future from the commonly used cut-off of ≥75 years of age. Physiological rather than chronological age is key. BC care in the elderly is likely to become a very common problem in daily practice. Concerns have been raised that senior BC patients are not given treatments that could cure their disease. Clinicians lack quantitative and reliable estimates of competing mortality risks when considering treatments for BC. Majority of patients diagnosed with BC are elderly, making treatment decisions complex with their increasing number of comorbidities. A multidisciplinary approach to these patients may be a way to incorporate discussion from various disciplines regarding treatment options available. Here we review various treatment options for elderly patients with muscle invasive BC and nonmuscle invasive BC. We include differences in treatments from robotic versus open radical cystectomy, various urinary diversion techniques, chemotherapy, radiation therapy and combination treatments. In clinical practice, treatment decisions for elderly patients should be done on a case-by-case basis, tailored to each patient with their specific histories and comorbidities considered. Some healthy elderly patients may be better candidates for extensive curative treatments than their younger counterparts. This implies that these important, life-altering decisions cannot be solely based on age as many other factors can affect patient survival outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.